Figure 2
Figure 2. FTI treatment suppresses T-cell lineage–specific cytokine production. Th1 (A) and Th2 (B) T cells were preincubated with varying concentrations (0-10 μM) of FTI CP 390392 for 24 hours followed by stimulation with beads coated with anti-CD3 (2C11, 1 μg/mL) plus anti-CD28 (PV1, 1 μg/mL) antibodies or PMA/ionomycin. Cell activation took place in the presence of indicated concentrations of FTI during the whole culture period. After an additional 18 hours, culture supernatants were analyzed by ELISA for lineage-specific cytokine content (IL-2, IL-4, IL-5, IFN-γ). Stimulations at distinct concentrations were performed in triplicate. Error bars are SD. Cytokine levels were undetectable in the absence of stimulation (data not shown).

FTI treatment suppresses T-cell lineage–specific cytokine production. Th1 (A) and Th2 (B) T cells were preincubated with varying concentrations (0-10 μM) of FTI CP 390392 for 24 hours followed by stimulation with beads coated with anti-CD3 (2C11, 1 μg/mL) plus anti-CD28 (PV1, 1 μg/mL) antibodies or PMA/ionomycin. Cell activation took place in the presence of indicated concentrations of FTI during the whole culture period. After an additional 18 hours, culture supernatants were analyzed by ELISA for lineage-specific cytokine content (IL-2, IL-4, IL-5, IFN-γ). Stimulations at distinct concentrations were performed in triplicate. Error bars are SD. Cytokine levels were undetectable in the absence of stimulation (data not shown).

Close Modal

or Create an Account

Close Modal
Close Modal